ID   SNB-78
AC   CVCL_B321
SY   SNB78; Surgical Neurology Branch-78
DR   ChEMBL-Cells; CHEMBL3307969
DR   ChEMBL-Targets; CHEMBL612543
DR   Cosmic; 1436043
DR   IARC_TP53; 21646
DR   NCI-DTP; SNB-78
DR   PubChem_Cell_line; CVCL_B321
DR   Wikidata; Q54955043
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=2041050;
RX   PubMed=3121170;
RX   PubMed=15900046;
RX   PubMed=22336246;
WW   Info; NCI DTP; NCI-60 additional lines; https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
CC   Part of: JFCR39 cancer cell line panel.
CC   Doubling time: 50 +- 2 hours (PubMed=3121170).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro223Ala (c.667C>G); Zygosity=Unspecified (PubMed=15900046).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 23
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister, Monica
RA   Westermark, Bengt
RT   "Human glioma cell lines.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay, Robert J. & Park, Jae-Gahb & Gazdar, Adi F. (eds.); pp.17-42; Academic Press; New York; USA (1994).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks, Anne
RA   Scudiero, Dominic A.
RA   Skehan, Philip
RA   Shoemaker, Robert H.
RA   Paull, Kenneth D.
RA   Vistica, David T.
RA   Hose, Curtis D.
RA   Langley, John
RA   Cronise, Paul
RA   Vaigro-Wolff, Anne
RA   Gray-Goodrich, Marcia
RA   Campbell, Hugh
RA   Mayo, Joseph G.
RA   Boyd, Michael R.
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=3121170;
RA   Gross, Janet L.
RA   Behrens, Davette Lynn
RA   Mullins, Deborra E.
RA   Kornblith, Paul Lee
RA   Dexter, Daniel L.
RT   "Plasminogen activator and inhibitor activity in human glioma cells
RT   and modulation by sodium butyrate.";
RL   Cancer Res. 48:291-296(1988).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima, Tetsuo
RA   Oh-hara, Tomoko
RA   Sato, Shigeo
RA   Mochizuki, Mikiko
RA   Sugimoto, Yoshikazu
RA   Yamazaki, Kanami
RA   Hamada, Jun-ichi
RA   Tada, Mitsuhiro
RA   Moriuchi, Tetsuya
RA   Ishikawa, Yuichi
RA   Kato, Yo
RA   Tomoda, Hiroshi
RA   Yamori, Takao
RA   Tsuruo, Takashi
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong, De-Xin
RA   Yamori, Takao
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//